London, UK - 27 April 2021: Oxford Biomedica plc ("Oxford Biomedica", "the Company" or "the Group") (LSE:OXB), a leading gene and cell therapy group, gives notice that copies of the 2020 Annual report and accounts and the Notice of Annual General Meeting ("AGM") have been sent to shareholders. These documents are available on the "Investors" section of the Group's website at www.oxb.com. Oxford Biomedica plc announced its preliminary results for the year ended 31 December 2020 on 15 April 2021.
Copies of these documents have been submitted to the Financial Conduct Authority for publication through the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Further copies of the 2020 Annual report and accounts are available from the Company Secretary, Oxford Biomedica plc, Windrush Court, Transport Way, Oxford, OX4 6LT, United Kingdom (telephone number: +44 (0) 1865 783 000).
Oxford Biomedica plc intends to hold its AGM on Thursday 27 May 2021 at the offices of Oxford Biomedica plc, Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m. Shareholders will not be allowed to attend the AGM in light of the ongoing COVID-19 situation and the restrictions on public gatherings that have been implemented by the UK Government. Unfortunately this means shareholders will not be able to attend the AGM in person but the Company is pleased to be able to offer facilities for Shareholders to attend virtually, ask questions and vote at the AGM electronically in real time should they wish to do so. The details of how to do this are set out in the Notice of Annual General Meeting.
In accordance with the requirements of Rule 6.3.5 of the Disclosure Guidance and Transparency Rules of the UK Financial Conduct Authority, the appendix to this announcement contains descriptions of the principal risks and uncertainties affecting the Group and material related party transactions, and a responsibility statement which has been extracted from the 2020 Annual report and accounts. This announcement should be read in conjunction with, and not as a substitute for, reading the full 2020 Annual report and accounts.
- Ends -
For further information, please contact:
Oxford Biomedica plc
Natalie Walter, Company Secretary
Tel: +44 (0)1865 783 000